Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Return to homepage

Marketwired News Releases

Mar 14, 2018 08:00 ET
Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program of CaPre in Severe Hypertriglyceridemia
Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST) today announced that the first patient has been randomized in the company's TRILOGY Phase 3 program evaluating lead drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), a condition of elevated triglycerides (TGs) in the bloodstream that increases the risk of coronary artery disease and pancreatitis.
Mar 14, 2018 07:58 ET
Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program of CaPre in Severe Hypertriglyceridemia
Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST) today announced that the first patient has been randomized in the company's TRILOGY Phase 3 program evaluating lead drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe...
Mar 14, 2018 07:55 ET
BBX Capital Corporation Announces Intention to Commence a Cash Tender Offer for Shares of its Class A Common Stock
BBX Capital Corporation (NYSE: BBX) (OTCQX: BBXTB) ("BBX Capital") announced today that it intends to commence a cash tender offer to purchase up to 6,486,486 shares of its Class A Common Stock at a purchase price of $9.25 per share. The closing...
Mar 14, 2018 07:30 ET
MagneGas Generates Record Sales in February 2018
MagneGas Corporation ("MagneGas" or the "Company") (NASDAQ: MNGA), a leading clean technology company in the renewable resources and environmental solutions industries, announced today that the Company generated record sales of $505,000 for the...
Mar 14, 2018 07:01 ET
Stella-Jones Increases Quarterly Dividend by 9.1%
The Board of Directors of Stella-Jones Inc. (TSX: SJ) is pleased to announce that a quarterly dividend of $0.12 per share, representing an increase of 9.1% over the previous quarterly dividend, has been declared on the outstanding common shares of the Corporation, payable on April 27, 2018 to shareholders of record at the close of business on April 6, 2018. This dividend is designated to be an eligible dividend.
Mar 14, 2018 07:00 ET
Perma-Fix Reports Results for the Fourth Quarter and Fiscal 2017
Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the "Company") today announced results for the fourth quarter and full year ended December 31, 2017.Mark Duff, Chief Executive Officer, stated, "We achieved $2.4 million of adjusted EBITDA (as...
Mar 14, 2018 07:00 ET
Stella-Jones Reports 2017 Fourth Quarter and Annual Results
Mar 14, 2018 07:00 ET
Stingray Launches a Music Blog
Stingray (TSX: RAY.A)(TSX: RAY.B)
Mar 14, 2018 06:59 ET
Stella-Jones Increases Quarterly Dividend by 9.1%
The Board of Directors of Stella-Jones Inc. (TSX:SJ) is pleased to announce that a quarterly dividend of $0.12 per share, representing an increase of 9.1% over the previous quarterly dividend, has been declared on the outstanding common shares of...
Mar 14, 2018 06:58 ET
Stella-Jones Reports 2017 Fourth Quarter and Annual Results
Sales of $1.89 billion in 2017, up 2.6% from $1.84 billion in 2016 9.1% increase in net income in 2017 to $167.9 million, versus $153.9 million a year ago 2017 diluted EPS of $2.42, up from $2.22 last year...
Mar 14, 2018 06:00 ET
Tetra Bio-Pharma Announces FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP)(OTCQB: TBPMF), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the active ingredients of its PPP001 drug (delta-9-tetrahydrocannabinol 9.5% and cannabidiol 2.5%) for the treatment of complex regional pain syndrome (CRPS). The Orphan Drug Designation was granted for the active moiety of the drug PPP001 and not the formulation.
Mar 14, 2018 05:58 ET
Tetra Bio-Pharma Announces FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the active ingredients of its PPP001 drug...
Mar 14, 2018 03:05 ET
Novoheart Opens New State-Of-The-Art Facilities at the Hong Kong Science Park
Novoheart ("Novoheart" or the "Company") (TSX VENTURE: NVH)(FRANKFURT: 3NH) is pleased to announce the opening of its brand new Hong Kong facility consisting of 5,300 ft2 of integrated laboratory and office space. Located in the Hong Kong Science Park, the laboratory is equipped with state-of-the-art facilities for stem cell production, tissue engineering and world-class research and development. The facility provides Novoheart with a new level of scalability enabling it to accommodate a significant number of additional revenue-generating commercial contracts and projects.
Mar 14, 2018 03:03 ET
Novoheart Opens New State-Of-The-Art Facilities at the Hong Kong Science Park
Novoheart ("Novoheart" or the "Company") (TSX VENTURE:NVH)(FRANKFURT:3NH) is pleased to announce the opening of its brand new Hong Kong facility consisting of 5,300 ft² of integrated laboratory and office space. Located in the Hong Kong Science...
Mar 13, 2018 20:02 ET
Brio Gold Reports Fourth Quarter and Full Year 2017 Financial Results
BRIO GOLD INC. (TSX: BRIO) ("BRIO GOLD" or the "Company") announces its fourth quarter and full year 2017 financial and operating results. All dollar figures are in U.S. dollars unless otherwise indicated.   Q4 and Full Year 2017 Summary Financial...
Mar 13, 2018 16:05 ET
VIVUS Reports Fourth Quarter 2017 Financial Results
VIVUS,Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results...
Mar 13, 2018 13:00 ET
Primero Announces Shareholders Vote in Favour of Transaction With First Majestic
Primero Mining Corp. ("Primero" or the "Company") (TSX: P) and First Majestic Silver Corp. ("First Majestic") (TSX: FR) (NYSE: AG) are pleased to announce that Primero's shareholders have voted in favour of the arrangement transaction (the...
Mar 13, 2018 12:23 ET
Rodizio Grill(R) To Reopen at The Liberty Center
Rodizio Grill® is reopening its location at the Liberty Center in Liberty Township, OH this spring. Rodizio Grill - Liberty Center is opening under new franchise ownership of George Chaposky, who has been successfully operating Rodizio Grill in...
Mar 13, 2018 10:21 ET
CLS Holdings USA's Acquisition Target Oasis Cannabis Finalizes Plans to Expand Capacity
CLSHoldings USA, Inc. (OTCQB: CLSH) "CLS," a development stage diversified cannabis company operating as Cannabis LifeSciences, today announced that its planned acquisition target, Oasis Cannabis, has finalized construction plans for the initial...
Mar 13, 2018 10:00 ET
Building Markets Transforms Entrepreneurial Learning Across the Globe With D2L
D2L, the global learning technology leader, today announced that nonprofit Building Markets is leveraging its learning platform, Brightspace, to train local businesses in countries affected by crisis. Building Markets is a nonprofit organization...